Kinarus Therapeutics Holding AG KNRS

SWX: KNRS | ISIN: CH0009115129 3/05/2024

9,754 CHF (-15,18%)

(-15,18%) 3/05/2024

Grafiek Kinarus Therapeutics Holding AG

Grafiek Kinarus Therapeutics Holding AG

1 dag1d -15,18%
1 week1w -41,77%
1 maand1m 232.138,10%
3 maanden3m 162.466,67%
6 maanden6m 1.219.150,00%
1 jaar1j 103.665,96%
5 jaar5j 54.088,89%

Kinarus Therapeutics Holding AG in het nieuws

Toon enkel gratis nieuws

12 juli 2023 · Kinarus Therapeutics Announces Personnel Change · Persbericht

29 juni 2023 · Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting · Persbericht

27 juni 2023 · Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity · Persbericht

2 juni 2023 · Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting · Persbericht

31 mei 2023 · Kinarus Therapeutics Group Reports 2022 Annual Results · Persbericht

11 mei 2023 · Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management · Persbericht

5 mei 2023 · Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures · Persbericht

28 april 2023 · Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report · Persbericht

21 februari 2023 · Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update · Persbericht

17 januari 2023 · Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan · Persbericht

Profiel Kinarus Therapeutics Holding AG

CEO: Jean-Claude Roch

Werknemers: 47

Aandelen Kinarus Therapeutics Holding AG

Beurswaarde: 4,72 miljoen CHF

Effecten: 1,31 miljard

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe